FoxP3+CD4+, IFN-γ+CD4+, and IFN-γ+CD8+ cell levels in erosive and non-erosive types of oral lichen planus patients

糜烂型和非糜烂型口腔扁平苔藓患者的 FoxP3+CD4+、IFN-γ+CD4+ 和 IFN-γ+CD8+ 细胞水平

阅读:6
作者:Andy Sun, Yu-Hsueh Wu, Julia Yu-Fong Chang, Yi-Ping Wang, Chun-Pin Chiang, Jean-San Chia

Conclusion

Major EOLP patients tend to have significantly higher percentages of FoxP3+CD4+, IFN-γ+CD4+, and IFN-γ+CD8+ cells than healthy control subjects, NEOLP patients or minor EOLP patients, suggesting that FoxP3+CD4+ Treg cells are increased to modulate OLP disease activity. Increased number of IFN-γ-producing activated T cell may be involved in oral epithelial cell destruction in OLP patients.

Methods

Flow cytometry was used to count the FoxP3+CD4+, IFN-γ+CD4+, or IFN-γ+CD8+ cell levels in 183 OLP patients (67 major EOLP, 81 minor EOLP, and 35 NEOLP patients) and 20 healthy control subjects.

Purpose

Oral lichen planus (OLP) is a localized autoimmune oral mucosal disease. This study evaluated whether different types of OLP patients including erosive OLP (EOLP), major EOLP, minor EOLP, and non-erosive OLP (NEOLP) patients had significantly higher percentages of FoxP3+CD4+ or IFN-γ+CD4+ cells in total CD4+ cells, and of IFN-γ+CD8+ cells in total CD8+ cells than healthy control subjects and whether the patient's age had significant influences on these cell percentages in OLP patients. Materials and

Results

Major EOLP patients had a significantly higher FoxP3+CD4+ cell percentage than health control subjects (P = 0.049) or minor EOLP patients (P = 0.008). Major EOLP patients had a significantly higher IFN-γ+CD4+ or IFN-γ+CD8+ cell percentage than healthy control subjects, NEOLP patients, or minor EOLP patients (all P-values < 0.01). In addition, both 61-80 year and 41-60 year OLP patients had significantly higher IFN-γ+CD8+ cell percentages than healthy control subjects or 20-40 year OLP patients (all P-values < 0.005).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。